<bill session="117" type="s" number="1427" updated="2023-03-08T20:12:35Z">
  <state datetime="2021-04-28">REFERRED</state>
  <status>
    <introduced datetime="2021-04-28"/>
  </status>
  <introduced datetime="2021-04-28"/>
  <titles>
    <title type="display">Increasing Access to Biosimilars Act of 2021</title>
    <title type="official" as="introduced">A bill to establish a demonstration project to increase access to biosimilar biological products under the Medicare program.</title>
    <title type="short" as="introduced">Increasing Access to Biosimilars Act of 2021</title>
  </titles>
  <sponsor bioguide_id="C001056"/>
  <cosponsors>
    <cosponsor bioguide_id="B001267" joined="2021-04-28"/>
  </cosponsors>
  <actions>
    <action datetime="2021-04-28">
      <text>Introduced in Senate</text>
    </action>
    <action datetime="2021-04-28" state="REFERRED">
      <text>Read twice and referred to the Committee on Finance.</text>
    </action>
  </actions>
  <committees>
    <committee code="SSFI" name="Senate Finance" subcommittee="" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill session="117" type="h" number="2869" relation="unknown"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Congressional oversight"/>
    <term name="Government studies and investigations"/>
    <term name="Health care costs and insurance"/>
    <term name="Health information and medical records"/>
    <term name="Health programs administration and funding"/>
    <term name="Medicare"/>
    <term name="Prescription drugs"/>
  </subjects>
  <amendments/>
  <summary date="2021-06-15T16:16:25Z" status="Introduced in Senate">Increasing Access to Biosimilars Act of 2021

This bill requires the Centers for Medicare &amp; Medicaid Services to establish a demonstration project to evaluate the benefits of providing additional payments to providers of biosimilars under Medicare. Specifically, under the demonstration project, participating providers receive an additional payment based on the difference between the costs to the provider of furnishing the biosimilar and the cost if the provider had furnished the underlying reference biological product instead.</summary>
</bill>
